NICE Backs Five Treatments for Reimbursement

The UK’s National Institute for Health and Care Excellence has backed five treatments for reimbursement by NHS England.

Swiss drug giant Novartis was a big winner, with the cost watch dog recommending its Zykadia for the treatment of advanced anaplastic lymphoma kinase positive non-small-cell lung cancer.

NICE determined in a final appraisal that Zykadia — which costs roughly $7,200 for a 30-day supply — would likely prolong patient life and delay disease progression compared to supportive care.